Search Videos by Topic or Participant
Browse by Series:

Introduction: Expanded RAS Testing in Colorectal Cancer

Panelists Johanna Bendell, MD, Sarah Cannon; Marwan Fakih, MD, City of Hope; Heinz-Josef Lenz, MD, USC;John L. Marshall, MD, Georgetown; Ala
Published: Wednesday, Feb 26, 2014
For High-Definition, Click
Moderator John L. Marshall, MD, introduces a panel discussion focused on the treatments available in the second- and later-line setting for patients with metastatic colorectal cancer (CRC) with a conversation on the expanded definition for KRAS mutations. The conversation includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.

Until recently, KRAS mutation testing included only exon 2 at codons 12 and 13, notes Fakih. However, a better understanding of the pathway and improvements in detection tools now demonstrates that mutations in KRAS exon 3 and 4, including NRAS exon 2 and 3, are predictive of response to EGFR inhibitors in CRC, notes Lenz. In general, this expanded criteria results in 20% more patients being ineligible for treatment with EGFR inhibitors, such as cetuximab and panitumumab.

The collection of mutational analyses from several trials has provided ample evidence to begin expanded RAS testing, Bendell believes. Moreover, as a result of this new evidence, if a patient has recently started treatment with an EGFR inhibitor based on traditional KRAS criteria it may be beneficial to retest using the expanded criteria, the panelists believe.



Slider Left
Slider Right
For High-Definition, Click
Moderator John L. Marshall, MD, introduces a panel discussion focused on the treatments available in the second- and later-line setting for patients with metastatic colorectal cancer (CRC) with a conversation on the expanded definition for KRAS mutations. The conversation includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.

Until recently, KRAS mutation testing included only exon 2 at codons 12 and 13, notes Fakih. However, a better understanding of the pathway and improvements in detection tools now demonstrates that mutations in KRAS exon 3 and 4, including NRAS exon 2 and 3, are predictive of response to EGFR inhibitors in CRC, notes Lenz. In general, this expanded criteria results in 20% more patients being ineligible for treatment with EGFR inhibitors, such as cetuximab and panitumumab.

The collection of mutational analyses from several trials has provided ample evidence to begin expanded RAS testing, Bendell believes. Moreover, as a result of this new evidence, if a patient has recently started treatment with an EGFR inhibitor based on traditional KRAS criteria it may be beneficial to retest using the expanded criteria, the panelists believe.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x